|
|
|
|
|
|
|
M Tue W Th F |
|
13 October, 2026 |
|
|
sponsored by
|
|
|
|
Delegate the Groundwork. Free Your Schedule to Advance the Science.
|
| Are you losing days chasing records across systems and assembling evidence before an investigation can begin? Katalyze AI delegates the groundwork to agents that gather the evidence and draft reports for you, with every finding connected back to its source. You review the results, challenge them in plain language, and decide what happens next. Built for GxP environments, Katalyze offers solutions for Yield Optimization, Deviation Investigation, Tech Transfer, and Raw Material Characterization. |
|
|
|
|
|
|
|
|
|
|
|
|
|
We were deeply saddened to learn of the passing of STAT journalist Helen Branswell, who has been a force on the public health and infectious disease beat for many years. Thank you for your reporting and writing, and for making your readers smarter, Helen. |
|
|
|
Drew Armstrong |
Executive Editor, Endpoints News
@ArmstrongDrew
|
|
|
|
|
|
|
by Nicole DeFeudis
|
Martin Shkreli is under FTC scrutiny once again. The agency and seven states asked a New York federal court on Tuesday to hold Shkreli in... | |
|
|
|
|
|
|
by Kyle LaHucik, Elizabeth Cairns
|
Verdiva Bio, one of the best-funded private biotechs seeking to get into the lucrative obesity drug market, has terminatedone of the Phase 2 trials... | |
|
|
|
|
|
|
by Max Bayer
|
There is some good news in the world of antibiotics. Novartis quietly snagged supplemental FDA approval for its drug Lamprene over the summer, transitioning a decades-old... | |
|
|
|
|
|
|
by Kyle LaHucik
|
A Bob Langer-affiliated startup has collected a megaround to advance at least three experimental oligonucleotide medicines. Soufflé Therapeutics uncorked a fresh $135 millionin VC... | |
|
|
|
|
|
| . |
 |
|
|
|
by Ryan Cross
|
For decades, Rudolph Tanzi has dreamt of a “little white pill” to prevent Alzheimer’s disease that would be so cheap and so safe, it could... | |
|
|
|
|
|
|
by Lei Lei Wu
|
An experimental mRNA cancer vaccine from BioNTech failed to meet one of two pri |
|
|
